HTR1A and major depressive disorder: Vilazodone, as a novel selective SSRI, has attracted attention for its prominent agonistic effects on the 5-HT1A receptor and a longer half-life, promising to further improve the clinical cure rates for MDD and enhance patient medication adherence.